- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05754853
A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer
An Open-label, Randomized, Multi-center, Phase III Clinical Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Urothelial Cancer Previously Treated With Platinum-based Chemotherapy and PD-1/PD-L1 Inhibitors
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100000
- Recruiting
- Cancer Hospital Chinese Academy of Medical Sciences
-
Contact:
- Aiping Zhou, MD
- Phone Number: 86-10-87788800
- Email: zhouap1825@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
1. Willing to sign the ICF and follow the requirements specified in the protocol.
2. Aged 18 to 75 (including 18 and 75), both genders. 3. Expected survival time ≥ 12 weeks. 4. Patients with unresectable locally advanced or metastatic urothelium cancer confirmed by histopathology.
5. Patients who have failed prior platinum-based chemotherapy and PD-1/PD-L1 inhibitors and have have progressive disease or recurrence on or after their most recent therapy.
6. Archival or biopsy tumor specimens should be provided (primary or metastatic).
7. HER2 positive (IHC 3+ or IHC 2+) in the tumor specimens confirmed by central laboratory test.
8. Patients must have measurable lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
9. ECOG performance score 0 or 1. 10. Prior anti-tumor treatment-related AEs (NCI-CTCAE v5.0 Criteria) have recovered to ≤ Grade 1 (except alopecia, Grade 2 hypothyroidism, non-clinically significant or asymptomatic laboratory abnormalities).
11. Organ function must meet the basic requirements. 12. Patients of childbearing potential must take effective contraceptive measures during the treatment and for 180 days after the last dose of treatment.
Exclusion Criteria:
1. History of hypersensitivity to any component of MRG002 or history of hypersensitivity of ≥ Grade 3 to trastuzumab.
2. Patients who have received ADC drugs, or prior taxane, gemcitabine, and pemetrexed for locally advanced or metastatic urothelial cancer; or have received investigational drugs from other clinical trials, chemotherapy, radiotherapy, targeted therapy, or immunotherapy within 4 weeks prior to the first dose; or have received Chinese medicine (herbal medicine) or Chinese patent medicine with anti-tumor indications within 2 weeks prior to the first dose; or have received strong CYP3A4 inhibitors within 2 weeks prior to the first dose or have current requirement of CYP3A4 inhibitors; or had major surgery within 4 weeks prior to the first dose without full recovery or planned surgery within 12 weeks after study treatment.
3. Patients with clinical symptoms such as plural, abdominal or pericardial effusion requiring puncture drainage.
4. Patients with central nervous system (CNS) metastasis and/or neoplastic meningitis.
5. Any severe or uncontrolled systemic diseases. 6. Patients with poorly controlled heart diseases. 7. Evidence of active infections, including but not limited to Hepatitis B, Hepatitis C, or human immunodeficiency virus (HIV) infection.
8. History of other primary malignancies. 9. History of interstitial pneumonia, severe chronic obstructive pulmonary disease, severe pulmonary insufficiency, symptomatic bronchospasm, etc.
10. Peripheral neuropathy greater than Grade 1. 11. History of cirrhosis. 12. Patients with active autoimmune disease or a history of autoimmune disease, who are using immunosuppressive agents, or systemic hormone therapy and still receiving them within 2 weeks prior to enrollment.
13. Uncontrolled tumor-associated bone pain or urgent spinal cord compression. Patients requiring pain control must have been on a stable treatment regimen for at least 2 weeks at the time of first dose 14. Other conditions inappropriate for participation in this clinical trial, at the discretion of the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MRG002
MRG002 will be administrated by an IV infusion of 2.2 mg/kg on Day 1 of every 3 weeks (21-day cycle).
|
Administrated intravenously
Administrated intravenously
Administrated intravenously
Administrated intravenously
|
Active Comparator: Docetaxel /Paclitaxel /Gemcitabine Hydrochloride /Pemetrexed Disodium Injection
Docetaxel injection will be administered by an IV infusion of 75 mg/m2 on Day 1 of every 3 weeks (21-day cycle); Paclitaxel will be administrated by an IV infusion of 175 mg/m2 on Day 1 of every 3 weeks (21-day cycle). Gemcitabine Hydrochloride will be administrated by an IV infusion of 1000 mg/m2 on Day 1 and Day 8 of every 3 weeks (21-day cycle). Pemetrexed Disodium will be administrated by an IV infusion of 500 mg/m2 on Day 1 of every 3 weeks (21-day cycle). |
Administrated intravenously
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: Baseline to study completion (up to 36 months)
|
OS is defined as the time from the date of randomization until death of any cause.
|
Baseline to study completion (up to 36 months)
|
Progression-Free Survival (PFS) by Independent Review Committee (IRC)
Time Frame: Baseline to study completion (up to 36 months)
|
PFS is defined as the duration from the date of randomization to the onset of tumor progression or death of any cause.
|
Baseline to study completion (up to 36 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events (AEs)
Time Frame: Baseline to 30 days after the last dose of study treatment
|
Any reaction, side effect, or untoward event that occurs during the course of the clinical trial whether or not the event is considered related to the study drug.
|
Baseline to 30 days after the last dose of study treatment
|
Objective Response Rate (ORR)
Time Frame: Baseline to study completion (up to 36 months)
|
ORR is defined as the percentage of patients with a complete response (CR) or partial response (PR) according to RECIST v1.1.
|
Baseline to study completion (up to 36 months)
|
Duration of Response (DoR)
Time Frame: Baseline to study completion (up to 36 months)
|
DoR is defined as the time from first documented objective response (CR/PR) to the first onset of tumor progression or death of any nonsurgical cause.
|
Baseline to study completion (up to 36 months)
|
Disease Control Rate (DCR)
Time Frame: Baseline to study completion (up to 36 months)
|
DCR is defined as the percentage of patients who achieve CR, PR, and stable disease (SD).
|
Baseline to study completion (up to 36 months)
|
Clinical Benefit Rate (CBR)
Time Frame: Baseline to study completion (up to 36 months)
|
CBR is defined as the percentage of patients who achieve CR, PR, and SD for ≥ 6 months.
|
Baseline to study completion (up to 36 months)
|
Time to Response (TTR)
Time Frame: Baseline to study completion (up to 36 months)
|
TTR is defined as the duration from randomization to the first documented objective response (CR/PR).
|
Baseline to study completion (up to 36 months)
|
PFS by investigator
Time Frame: Baseline to study completion (up to 36 months)
|
PFS is defined as the duration from the date of randomization to the onset of tumor progression or death of any cause.
|
Baseline to study completion (up to 36 months)
|
Pharmacokinetics (PK) Parameter of MRG002: concentration-time curve
Time Frame: Baseline to 7 days after discontinuation of treatment
|
Plot of drug concentration changing with time after drug administration.
|
Baseline to 7 days after discontinuation of treatment
|
Anti-drug antibody (ADA)
Time Frame: Baseline to 7 days after discontinuation of treatment
|
The proportion of patients with positive ADA results and its titer.
|
Baseline to 7 days after discontinuation of treatment
|
Neutralizing antibody (NAb)
Time Frame: Baseline to 7 days after discontinuation of treatment
|
The proportion of patients with positive NAb results and its titer.
|
Baseline to 7 days after discontinuation of treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Aiping Zhou, MD, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Principal Investigator: Fangjian Zhou, MD, Sun Yat-sen University Cancer Prevention Center
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Folic Acid Antagonists
- Gemcitabine
- Docetaxel
- Paclitaxel
- Pemetrexed
Other Study ID Numbers
- MRG002-010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced or Metastatic Urothelium Cancer
-
Jiangsu Simcere Pharmaceutical Co., Ltd.UnknownAdvanced or Metastatic Gastric Cancer | Advanced or Metastatic CRC | Advanced or Metastatic Liver Cancer | Advanced or Metastatic Non Squamous NSCLCChina
-
Shanghai Miracogen Inc.RecruitingAdvanced Solid Tumors | Advanced or Metastatic Gastric Cancer | Advanced or Metastatic Gastroesophageal Junction CancerUnited States
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Merck Sharp & Dohme LLCCompletedMetastatic or Locally Advanced Cancer
-
Gilead SciencesEverest MedicinesActive, not recruitingLocally Advanced or Metastatic Unresectable Urothelial CancerUnited States, Belgium, France, Spain, United Kingdom, Korea, Republic of, Czechia, Germany, Israel, China, Italy, Australia, Hong Kong, Taiwan, Portugal, Singapore, Croatia, Greece, Turkey, Sweden, Switzerland, Canada, Austria, Bulgaria and more
-
Taiho Oncology, Inc.Active, not recruitingAdvanced or Metastatic Solid Tumor | Advanced or Metastatic Gastric or Gastroesophageal Cancer | Myeloid or Lymphoid Neoplasms (MLN)United States, Spain, Turkey, Hong Kong, Korea, Republic of, Belgium, Japan, Netherlands, France, Germany, Italy, Sweden, United Kingdom, Portugal, Singapore
-
AstraZenecaCompletedAdvanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast CancerCanada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria
-
University of UtahCelgene CorporationCompletedAdvanced or Metastatic Solid Tumors | Advanced or Metastatic Breast CancerUnited States
-
ASLAN PharmaceuticalsCompletedAdvanced or Metastatic Solid Tumors | Advanced or Metastatic Biliary Tract CancerJapan
-
ImmunoGen, Inc.WithdrawnStomach Neoplasms | Metastatic or Locally Advanced Gastric Cancer | Metastatic or Local Advanced GE Junction CancerUnited States
Clinical Trials on MRG002
-
Shanghai Miracogen Inc.RecruitingLocally Advanced Gastric Cancer | Metastatic HER2 Positive Gastroesophageal Junction CancerChina
-
Shanghai Miracogen Inc.RecruitingAdvanced Solid TumorChina
-
Shanghai Miracogen Inc.RecruitingAdvanced or Metastatic Biliary Tract CancerChina
-
Shanghai Miracogen Inc.Not yet recruitingNon-small- Cell Lung Cancer (NSCLC)China
-
Shanghai Miracogen Inc.RecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial CancerChina
-
Shanghai Miracogen Inc.RecruitingAdvanced or Metastatic Breast CancerChina
-
Shanghai Miracogen Inc.RecruitingAdvanced Solid Tumors | Advanced or Metastatic Gastric Cancer | Advanced or Metastatic Gastroesophageal Junction CancerUnited States
-
Shanghai Miracogen Inc.RecruitingBreast Cancer With Liver MetastasesChina
-
Shanghai Miracogen Inc.RecruitingAdvanced Malignant Solid TumorsChina
-
Shanghai Miracogen Inc.RecruitingAdvanced Breast Cancer | Metastatic Breast CancerChina